October 05, 2020 04:13 ET | Source: Immunophotonics, Inc. BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the treatment of solid and metastatic cancers, has bolstered its expertise through the appointment of Jonathan Knowles, Ph.D. to its Board...
Category: Latest News
Immunophotonics Receives Swissmedic Approval to Commence Phase 1B/2A Clinical Trial in Switzerland
Immunophotonics has received Swissmedic approval to commence a new clinical trial entitled “Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.” This is a multicenter phase 1B/2A trial with expansion cohorts in melanoma and soft tissue sarcoma patients. The therapeutic approach taken by this trial (SAKK 66/17) is different from those...
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and IRVINE, Calif., June 14, 2019 (GLOBE NEWSWIRE) — Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial...